YAP1 and breast cancer: Another example of oncomiR is miR-200a, which promotes epithelial–mesenchymal transition (EMT), drug resistance and metastasis by targeting tumor protein P53-inducible nuclear protein 1 (TP53INP1) and yes-associated protein 1 (YAP1) in human BC [155,156].